Dual <scp>TLR7</scp> /8 Activation by Dihydroxyimidazoquinoline Adjuvant Orchestrates <scp>NF</scp> ‐κβ‐ <scp>iNOS</scp> ‐Driven Th1 Immunity and Durable Protection Against <i>Leishmania donovani</i>
T cell subsets in the high-dose groups supporting durable adaptive immunity. The dual TLR7/8 activity of this compound mediated broad and sustained immunoregulatory signalling that surpassed resiquimod in magnitude and persistence. Collectively, this study delineated a mechanistic framework for TLR7/8 driven immunoregulation and establishes dihydroxyimidazoquinoline as a next-generation adjuvant for rational, host-directed vaccine design against intracellular pathogens such as L. donovani.
Authors
- Sukhbir Kaur (ORCID: https://orcid.org/0000-0001-9071-7950)
- Deepak B. Salunke (ORCID: https://orcid.org/0000-0002-1241-9146)
- Shivani Thakur
- Sandeep Kaur (ORCID: https://orcid.org/0000-0001-7818-5285)
- Kushvinder Kumar
Institutions
- National Institute of Pharmaceutical Education and Research - Ahmedabad (IN)
- National Institute of Pharmaceutical Education and Research (IN)
- National Institute of Pharmaceutical Education and Research (IN)
- Panjab University (IN)
Publication Details
- Journal
- Immunology
- Published
- 2026-04-12
- DOI
- https://doi.org/10.1111/imm.70137
- Primary Topic
- Research on Leishmaniasis Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Indian Council of Medical Research
- Council of Scientific and Industrial Research, India